KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

LifeMD (LFMD) EPS (Weighted Average and Diluted) (2016 - 2025)

LifeMD (LFMD) has disclosed EPS (Weighted Average and Diluted) for 12 consecutive years, with $0.42 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 450.0% year-over-year to $0.42, compared with a TTM value of $0.25 through Dec 2025, up 139.68%, and an annual FY2025 reading of $0.25, up 139.06% over the prior year.
  • EPS (Weighted Average and Diluted) was $0.42 for Q4 2025 at LifeMD, up from -$0.1 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.42 in Q4 2025 and bottomed at -$0.64 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.25, with a median of -$0.2 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) tumbled 137.04% in 2021, then skyrocketed 450.0% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.64 in 2021, then skyrocketed by 37.5% to -$0.4 in 2022, then skyrocketed by 70.0% to -$0.12 in 2023, then changed by 0.0% to -$0.12 in 2024, then surged by 450.0% to $0.42 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for LFMD at $0.42 in Q4 2025, -$0.1 in Q3 2025, and -$0.05 in Q2 2025.